Two Articles published in this week's issue highlight the potential of whole-exome sequencing to increase the possibility of a genetic diagnosis when fetal structural anomalies are detected. In both studies, fetuses were prospectively included if structural anoma lies were detected through routine prenatal ultrasound and if no aneuploidy or large copy number variants were confirmed. Fetal and parental wholeexome sequencing showed clinically significant genetic variants in 8·5% of fetuses in one study and 10·3% in the other. These studies present another step towards better parental counselling during pregnancy and for future pregnancies and prognostic information for clinical decision making.
Routine prenatal screening has evolved from a single maternal serum marker (alpha-fetoprotein) for the dete ction of neural tube defects, to the now widely offered combination of two ultrasound examinations in the first and second trimester and several maternal serum markers. These tests can be followed by diagnostic testing, such as karyotyping by amniocentesis or chorionic villus sampling, if anomalies suggestive of a chromosome disorder, such as Down's syndrome, Edward's syndrome, or Patau's syndrome, are detected and parents wish to undergo such testing. Beyond screening and diagnosis, there is also the developing field of fetal therapy, providing options for intrapartum medical or surgical interventions for some fetal anomalies. The first ever open fetal surgery was performed by Michael Harrison at the University of California, San Francisco, CA, USA, in 1981, when a vesicostomy was placed in a fetus with a urinary obstruction. Since then, procedures have been developed for a variety of fetal structural anomalies. They can be divided into open fetal surgical techniques, which require a hysterotomy (eg, myelomeningocele repair), fetoscopic techniques (eg, laser treatment of twin-twin transfusion syndrome), or ex-utero intrapartum treatment, which is a fetal intervention just before delivery but while the fetus is still connected to the placenta (eg, for major airway obstruction that would make a normal caesarean section too risky). Whereas, previously, procedures focused on avoiding fetal mortality, the goal is increasingly to change the natural history of diseases, such as avoiding lung hypoplasia due to congenital diaphragmatic hernia.
For intrapartum open myelomeningocele repair, robust evidence from a multicentre randomised trial (the Management of Myelomeningocele Study) showed a decreased need for shunting, reversal of hindbrain herniation, and better neurological function in the prenatal group than in the postnatally repaired group, with the trade-off of some maternal complications and increased frequency of prematurity. The first such repairs were done in the UK, in October, last year, by a team from Great Ormond Street Hospital, University College London, in partnership with the University Hospitals Leuven, Belgium.
Such maternal-fetal surgery, which involves two patients-the mother and the fetus-requires an extremely nuanced and thoughtful approach. Multidisciplinary teams are needed in the planning, the implementation, and follow up phases. If done under general anaesthesia, special expertise is required to take both the maternal and fetal physiological reactions and their interactions into account. Many issues must be carefully considered, such as maternal autonomy over fetal outcomes, with careful risk-benefit assessments for both mother and child when information on long-term outcomes is still unavailable and extrapolation from animal models is imperfect; striking the right balance between the need for interventions as part of research and innovation and unintentional coercion; when and how multicentre clinical trials should be planned; and what the ethically justified criteria are for the transition of an intervention to clinical practice.
The prevention or amelioration of major neonatal morbidity by detecting and treating fetal anomalies is an exciting prospect. But the fetal medicine field might evolve at a rapid pace. So far, no mandatory reporting or registry for fetal surgery exists, and socalled fetal intervention fellowships are not accredited, with further training mostly done on an apprenticeship basis. As a first step, fetal therapy centres should all transparently monitor and report outcomes of these procedures, and a formal international professional programme of fetal therapy training should be established. Discussion on processes to accredit fetal centres are underway in the USA, with Texas being the first state to pass a Bill to determine the elements for fetal centre excellence. Now is the time to anticipate fetal therapy's potential and pitfalls, and initiate prudent regulation and best practice. n The Lancet 
